Outcomes of cataract surgery with/without vitrectomy in patients with pars planitis and immunosuppressive therapy
Por:
Albavera-Giles T., Serna-Ojeda J.C., Jimenez-Corona A., Pedroza-Seres M.
Publicada:
1 ene 2017
Resumen:
Background: The purpose of this study was to evaluate the characteristics and outcomes of cataract surgery with/without vitrectomy in patients with pars planitis who received immunosuppressive therapy. Methods: This was a retrospective case series, single-center study. Twenty-two patients with pars planitis who received immunosuppressive therapy were included, with a median age at presentation of 9.5 years, having had cataract surgery. The following data was collected: age at presentation and at cataract surgery, time of follow-up, best-corrected visual acuity (BCVA) before the surgery and at 1 week, 1 and 6 months after the procedure, immunosuppressive therapy, complications and causes for failed visual improvement. The variables associated with an improvement in visual acuity were evaluated. Results: All patients had phacoemulsification with intraocular lens implantation. The most common immunosuppressive therapy used for the patients was methotrexate in nine patients (40.9%). The BCVA improved from a median of 20/400 to 20/100 after 6 months of follow-up (p = 0.0005); 14 patients (63.6%) improved two lines of vision or more. No significant risk factors were found for the association with improvement in visual acuity after the surgery. No improvement in visual acuity was attributed to posterior segment manifestations or amblyopia; the most common complication was posterior capsule opacification in 11 eyes (50%). The median follow-up after the surgery was 32 months. Conclusion: Phacoemulsification was the procedure for all the patients. Visual acuity improved in patients with pars planitis treated with immunosuppressive drugs who underwent cataract surgery, except for the patients with posterior segment complications or amblyopia. © 2017, Springer-Verlag Berlin Heidelberg.
Filiaciones:
Albavera-Giles T.:
Department of Uveitis and Ocular Immunology, Instituto de Oftalmologia “Conde de Valenciana”, Mexico City, Mexico
Serna-Ojeda J.C.:
Department of Uveitis and Ocular Immunology, Instituto de Oftalmologia “Conde de Valenciana”, Mexico City, Mexico
Jimenez-Corona A.:
Department of Uveitis and Ocular Immunology, Instituto de Oftalmologia “Conde de Valenciana”, Mexico City, Mexico
Pedroza-Seres M.:
Department of Uveitis and Ocular Immunology, Instituto de Oftalmologia “Conde de Valenciana”, Mexico City, Mexico
Instituto de Oftalmologia “Conde de Valenciana”, Chimalpopoca 14, Cuauhtémoc, Mexico City, 06800, Mexico
|